Luminal Breast Cancer Cryoablation
Cryoablation for the Treatment of Luminal Early Breast Cancer
Lucía Graña López
140 participants
Apr 8, 2026
INTERVENTIONAL
Conditions
Summary
LUBRECA will evaluate the safety and efficacy of cryoablation with liquid nitrogen to treat cT1cN0 luminal breast cancer diagnosed in postmenopausal women
Eligibility
Inclusion Criteria8
- Postmenopausal women diagnosed with invasive breast cancer by core needle biopsy or vacuum-assisted biopsy
- Unifocal
- Lesion ≤ 2 cm (on ultrasound and contrast enhanced mammography)
- No axillary lymphadenopathy on ultrasound
- No axillary lymph node involvement on ultrasound.
- Luminal tumor (estrogen and/or progesterone receptor positive)
- HER2 negative
- Signed informed consent
Exclusion Criteria6
- Infiltrating lobular carcinoma
- Extensive in situ component
- Multifocality or multicentricity
- Contraindication for contrast mammography
- Not candidate for surgery
- Distant metastasis -
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The appropriate cryoprobe (10G or 13G) will be selected depending on the size of the tumor. After injecting local anesthesia, the cryoprobe will be inserted along the longest diameter of the lesion. The tip of the needle will be advanced so that the freezing center is located in the middle of the tumor. Two freezing cycles will be performed, separated by a thawing cycle, all three of the same duration, which depends on the size of the tumor. The goal is a freezing volume with a lethal zone covering the lesion and a safety margin of at least 1 cm. Ultrasound allows real-time monitoring of the expansion of the ice ball during cryoablation. To avoid burning the skin, we will inject warm sterile saline solution when the distance between the ice and the skin surface is less than 0.5 cm
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07447414